Audio Journal of Oncology – June 3rd 2006, from the ASCO Annual Meeting in Atlanta, June 2-6; in the company of George Canellos

– Elderly patients with non-small cell lung cancer can benefit from chemotherapy after surgery, and do not experience increased toxicity when compared to younger patients – that’s according to Carmela Pepe of the Princess Margaret Hospital in Toronto (abstract 7009)
– the Oncology Drugs Advisory Committee has concluded that the drug dasatinib should be recommended for the treatment of chronic myeloid leukaemia. Breaking the news at the Atlanta meeting was John Goldman of Imperial College London, and the National Heart Lung and Blood Institute, NIH, Bethesda
– Roy Herbst from the MD Anderson Cancer Center in Houston tells the Audio Journal about some of the most exciting announcements to be made at the 2006 ASCO conference, including progress in multiple myeloma and targeted therapy in renal cancer
– the outgoing president of ASCO, Sandra Horning, of Stanford University, explains how ASCO has focussed on cancer survivorship over the last year – and how cancer survivors can expect to receive more support in the future.